Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)

Michael A. Badruddoja, Marjorie Pazzi, Abhay Sanan, Kurt Schroeder, Kevin Kuzma, Thomas Norton, Thomas Scully, Daruka Mahadevan, Michael Malek Ahmadi

Producción científica: Comment/debaterevisión exhaustiva

1 Cita (Scopus)

Resumen

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. The second sentence of the “Introduction” section should read as: A majority of these patients will have glioblastoma, the most malignant variant of glioma [1].

Idioma originalEnglish (US)
Páginas (desde-hasta)223
Número de páginas1
PublicaciónCancer chemotherapy and pharmacology
Volumen81
N.º1
DOI
EstadoPublished - ene 1 2018
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Cancer Research
  • Toxicology
  • Pharmacology

Huella

Profundice en los temas de investigación de 'Correction to: Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma (Cancer Chemotherapy and Pharmacology, (2017), 80, 4, (715-721), 10.1007/s00280-017-3405-7)'. En conjunto forman una huella única.

Citar esto